Amarin Sees Off-Label Claims Boosted By Study Results
Amarin Corp. PLC on Monday reported eye-popping cardiovascular benefits from its omega-3 drug Vascepa, lending credence to off-label uses the company was allowed to promote under a historic court ruling against...To view the full article, register now.
Already a subscriber? Click here to view full article